Serum Levels Evaluation of TMSB10 and Endocan in Breast Cancer Patients and In-Vitro Study of Chrysin Effect on These Markers in MCF-7 cell line

References

• Sharma GN, Dave R, Sanadya J, et al. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010;1(2):109.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Ca A Cancer J Clinicians. 2015;65(1):5–29. doi: 10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int. 2010;107(6):85. doi: 10.3238/arztebl.2010.0085
   PubMed Web of Science ®Google Scholar
• Weigelt B, Peterse JL, van’t Veer LJ. Van’t Veer LJJNrc: Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–602. doi: 10.1038/nrc1670
   PubMed Web of Science ®Google Scholar
• Milas L, Peters LJ, Ito H. Spontaneous metastasis: random or selective? Clinical & experimental metastasis. Clin Exp Metastasis. 1983;1(4):309–315. doi: 10.1007/BF00121193
   PubMed Web of Science ®Google Scholar
• Giavazzi R, Alessandri G, Spreafico F, et al. Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. Br J Cancer. 1980;42(3):462–472. doi: 10.1038/bjc.1980.259
   PubMed Web of Science ®Google Scholar
• Safer D, Golla R, Nachmias VT. Isolation of a 5-kilodalton actin-sequestering peptide from human blood platelets. Proc Nat Acad Sci. 1990;87(7):2536–2540. doi: 10.1073/pnas.87.7.2536
   PubMed Web of Science ®Google Scholar
• Sribenja S, Li M, Wongkham S, et al. Advances in thymosin β10 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Invest. 2009;27(10):1016–1022. doi: 10.3109/07357900902849640
   PubMed Web of Science ®Google Scholar
• Bouchal P, Dvořáková M, Roumeliotis T, et al. Combined proteomics and transcriptomics identifies carboxypeptidase B1 and nuclear factor κB (NF-κB) associated proteins as putative biomarkers of metastasis in low grade breast cancer. Molecular & Cellular Proteomics. 2015;14(7):1814–1830. doi: 10.1074/mcp.M114.041335
   PubMed Web of Science ®Google Scholar
• Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458–20464. doi: 10.1074/jbc.271.34.20458
   PubMed Web of Science ®Google Scholar
• Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta (BBA)- Rev Cancer. 2006;1765(1):25–37. doi: 10.1016/j.bbcan.2005.08.004
   PubMed Web of Science ®Google Scholar
• Yang J, Yang Q, Yu S, et al.: Endocan: A new marker for cancer and a target for cancer therapy. Biomedical reports 2015, 3(3):279–283.
   Google Scholar
• Lv Z, Fan Y, Chen H, et al. Endothelial cell-specific molecule-1: a potential serum marker for gastric cancer. Tumor Biol. 2014;35(10):10497–10502. doi: 10.1007/s13277-014-2319-9
   PubMedGoogle Scholar
• El Behery MM, Seksaka MA, Ibrahiem MA, et al. El Alfy Y: Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstetrics. 2013;288(6):1371–1376. doi: 10.1007/s00404-013-2863-3
   PubMed Web of Science ®Google Scholar
• Ates O, Gedik E, Sunar V, et al. Serum endocan level and its prognostic significance in breast cancer patients. J Oncological Sci. 2018;4(1):15–18. doi: 10.1016/j.jons.2017.11.004
   Google Scholar
• Mohammadian F, Abhari A, Dariushnejad H, et al. Upregulation of Mir-34a in AGS gastric cancer cells by a PLGA-PEG-PLGA chrysin nano formulation. Asian Pac J Cancer Prev. 2016;16(18):8259–8263. doi: 10.7314/APJCP.2015.16.18.8259
   Google Scholar
• Mohammadian F, Pilehvar-Soltanahmadi Y, Alipour S, et al. Chrysin alters microRnas expression levels in gastric cancer cells: possible molecular mechanism. Drug Res (Stuttg). 2017;67(9):509–514. doi: 10.1055/s-0042-119647
   PubMedGoogle Scholar
• Deldar Y, Pilehvar-Soltanahmadi Y, Dadashpour M, et al. Nanomedicine, biotechnology: An in vitro examination of the antioxidant, cytoprotective and anti-inflammatory properties of chrysin-loaded nanofibrous mats for potential wound healing applications. Artific Cells Nanomed Biotechnol. 2018;46(4):706–716. doi: 10.1080/21691401.2017.1337022
   PubMed Web of Science ®Google Scholar
• Mohammadian F, Pilehvar-Soltanahmadi Y, Zarghami F, et al. Upregulation of miR-9 and Let-7a by nanoencapsulated chrysin in gastric cancer cells. Artificial cells, nanomedicine, and biotechnology. Artific Cells Nanomed Biotechnol. 2017;45(6):1201–1206. doi: 10.1080/21691401.2016.1216854
   Web of Science ®Google Scholar
• Deldar Y, Pilehvar-Soltanahmadi Y, Dadashpour M, et al. An in vitro examination of the antioxidant, cytoprotective and anti-inflammatory properties of chrysin-loaded nanofibrous mats for potential wound healing applications. Artific Cells Nanomed Biotechnol. 2018;46(4):706–716. doi: 10.1080/21691401.2017.1337022
   PubMed Web of Science ®Google Scholar
• Deldar Y, Zarghami F, Pilehvar-Soltanahmadi Y, et al. Antioxidant effects of chrysin-loaded electrospun nanofibrous mats on proliferation and stemness preservation of human adipose-derived stem cells. Cell and tissue banking. Cell Tissue Bank. 2017;18(4):475–487. doi: 10.1007/s10561-017-9654-1
   PubMed Web of Science ®Google Scholar
• Chen Y-H, Yang Z-S, Wen C-C, et al. Evaluation of the structure–activity relationship of flavonoids as antioxidants and toxicants of zebrafish larvae. Food Chem. 2012;134(2):717–724. doi: 10.1016/j.foodchem.2012.02.166
   PubMed Web of Science ®Google Scholar
• Ahad A, Ganai AA, Mujeeb M, et al. Chrysin, an anti-inflammatory molecule, abrogates renal dysfunction in type 2 diabetic rats. Toxicol Appl Pharmacol. 2014;279(1):1–7. doi: 10.1016/j.taap.2014.05.007
   PubMed Web of Science ®Google Scholar
• Rasouli S, Zarghami N. Synergistic growth inhibitory effects of chrysin and metformin combination on breast cancer cells through hTERT and cyclin D1 suppression. Asian Pac J Cancer Prev: APJCP. 2018;19(4):977. doi: 10.22034/APJCP.2018.19.4.977
   PubMedGoogle Scholar
• Abotaleb M, Samuel SM, Varghese E, et al. Flavonoids in cancer and apoptosis. Cancers. 2019;11(1):28. doi: 10.3390/cancers11010028
   Web of Science ®Google Scholar
• Balam FH, Ahmadi ZS, Ghorbani AJH. Inhibitory effect of chrysin on estrogen biosynthesis by suppression of enzyme aromatase (CYP19): a systematic review. Heliyon. 2020;6(3):e03557. doi: 10.1016/j.heliyon.2020.e03557
   PubMed Web of Science ®Google Scholar
• Zhang X, Ren D, Guo L, et al. Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer. Breast Cancer Res. 2017;19(1):15. doi: 10.1186/s13058-016-0785-2
   PubMedGoogle Scholar
• Santelli G, Califano D, Chiappetta G, et al. Thymosin β-10 gene overexpression is a general event in human carcinogenesis. Am J Pathol. 1999;155(3):799–804. doi: 10.1016/S0002-9440(10)65178-4
   PubMed Web of Science ®Google Scholar
• Leroy X, Aubert S, Zini L, et al. Vascular endocan (ESM‐1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010;56(2):180–187. doi: 10.1111/j.1365-2559.2009.03458.x
   PubMed Web of Science ®Google Scholar
• Sarrazin S, Lyon M, Deakin JA, et al. Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan. Glycobiology. 2010;20(11):1380–1388. doi: 10.1093/glycob/cwq100
   PubMed Web of Science ®Google Scholar
• Celik ZE, Demir F, Yonar H, et al. Association of endocan expression with clinicopathological prognostic parameters in breast carcinoma. Cancer Biomarkers. 2021;2021(4):1–7. doi: 10.3233/CBM-201026
   Google Scholar
• Basim P, Argun D. A comparison of the circulating endocan levels between the inflammatory and malignant diseases of the same organ: the breast. J Invest Surg. 2021;2020(11):1–7. doi: 10.1080/08941939.2020.1792008
   Google Scholar
• Yang Y-C, Pan K-F, Lee W-J, et al. Circulating proteoglycan endocan mediates EGFR-driven progression of non–small cell lung cancer. Cancer Res. 2020;80(16):3292–3304. doi: 10.1158/0008-5472.CAN-20-0005
   PubMed Web of Science ®Google Scholar
• Samarghandian S, Azimi-Nezhad M, Borji A, et al. Inhibitory and cytotoxic activities of chrysin on human breast adenocarcinoma cells by induction of apoptosis. Phcog Mag. 2016;12(Suppl 4):S436. doi: 10.4103/0973-1296.191453
   Google Scholar
• Luo D, Wang X, Zhong X, et al. MPEG-PCL nanomicelles platform for synergistic metformin and chrysin delivery to breast cancer in mice. Anticancer Agents Med Chem. 2022;22(2):280–293 doi: 10.2174/1871520621666210623092725
   PubMed Web of Science ®Google Scholar